<DOC>
	<DOC>NCT02183142</DOC>
	<brief_summary>The objective of this study is to compare the pharmacokinetic parameters of the 7.5 mg Mobic tablet manufactured in china in comparison with 7.5 mg tablets manufactured in Germany</brief_summary>
	<brief_title>Study of Relative Bioavailability of Mobic Manufactured in China in Comparison With Mobic Manufactured in Germany in Chinese Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Meloxicam</mesh_term>
	<criteria>Chinese healthy male volunteers as determined by result of screening Written informed consent in accordance with Good Clinical Practice (GCP) Age &gt;= 18 and &lt;= 40 years Broca &gt; 20% and &lt; + 20% Any finding of the medical examination (blood pressure, pulse rate and Electrocardiogram (ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorder Surgery of the gastrointestinal tract (except appendectomy) Diseases of the central nervous system (such as epilepsy) or psychiatric disorders Chronic or relevant acute infections Hypersensitivity to Mobic and/or nonsteroidal antiinflammatory drugs Intake any drugs within 1 month before randomization Participation in another trial with an investigational drug within the last 2 month or during the trial Smokers ( &gt;= 10 cigarettes or &gt;= 3 cigars or &gt;= 3 pipes/day) or inability to refrain from smoking on study days Alcohol or drug abuse Blood donation within the last 1 month Excessive physical activities within the last 5 days History of hemorrhagic diatheses History of gastrointestinal ulcer, perforation or bleeding History of bronchial asthma</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>